Allspring Global Investments
ONCT

Allspring Global Investments’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Allspring Global Investments’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,251
Closed -$90K – 3010
2022
Q1 		$90K Sell
3,251
-3,810
-54% -$139K ﹤0.01% 2769
2021
Q4 		$320K Buy
+7,061
New +$475K ﹤0.01% 2476

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $4.53B AUM 21.1% 1-Year Est. Return

Allspring Global Investments's ONCT Position: Q2 2022 in Review

Allspring Global Investments sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2022, closing a stake of 3,251 shares — an estimated $90K sold.

Allspring Global Investments first reported a position in ONCT in Q4 2021 and held it in 2 quarters. The position peaked at $320K in Q4 2021. 75 funds tracked by Wall St. Rank hold ONCT as of Q2 2022.

  • Allspring Global Investments reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 3,251 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $90K.
  • Allspring Global Investments first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's Oncternal Therapeutics, Inc. Common Stock position peaked at $320K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.